← Leaderboards
Colleen T Harrington
University Of Pennsylvania
$120,651
Attributed
$120,651
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $44.5K · FY2017–19$50K$37.5K$25K$12.5K$0
'17
'18
'19
Funding mix
By agency
NIH$120,651 · 1
By mechanism
F31$120,651 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Lewis A Chodosh$38,386,361
- Xiaolu Yang$22,144,051
- Xiaowei Xu$9,845,570
- Wafik S El-Deiry$15,004,115
- Rumela Chakrabarti$2,408,691
Others in their field
Other Emerging Leaders on “Doxorubicin”
- Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ$4,167,074
- Ozgur Sahin · Medical University Of South Carolina$3,925,035
- Tzu-Yin Lin · Theranostec, Inc.$3,924,751
- Aarti Asnani · Beth Israel Deaconess Medical Center$3,921,462
- Ashley Smuder · University Of Florida$3,752,771
- Hui-Ming Chang · University Of Missouri-Columbia$3,417,937
Research focus
DoxorubicinApoptosisAdjuvant TherapyB-Cell LymphomasBiologyB Lymphoid MalignancyBurkitt LymphomaApoptoticCasp8 And Fadd-Like Apoptosis Regulating ProteinCell Cycle ArrestCell DeathCell GrowthCell LineCellsCell SurfaceCellular EngineeringCellular StressCessation Of LifeChemotherapyChromosomal TranslocationC-Myc Proto-OncogenesComplementCrispr/Cas TechnologyEvent
Grant awards (3)
Elucidating the mechanism of anti-GSK3 adjuvant therapy for Myc-driven lymphomas$32,083
F31 · FY2019 · CA · contact PI
Elucidating the mechanism of anti-GSK3 adjuvant therapy for Myc-driven lymphomas$44,524
F31 · FY2018 · CA · contact PI
Elucidating the mechanism of anti-GSK3 adjuvant therapy for Myc-driven lymphomas$44,044
F31 · FY2017 · CA · contact PI